New Substituted Oxindole Derivative 352

• US 20090291982A1
• Filed: 05/22/2008
• Published: 11/26/2009
• Est. Priority Date: 05/22/2008
• Status: Abandoned Application

• Current Assignee: Astrazeneca AB (Astrazeneca PLC)
• Original Assignee: Astrazeneca AB (Astrazeneca PLC)
• Inventors: Lake, Fredrik, IVERSON HEMBERG, Suzanne, Claesson, Martina
• Application Number:
  US12/125,619
• Publication Number:
  US 20090291982A1
• Time in Patent Office: Days
• US Class Current: 514/339
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 19/10 for osteoporosis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: C07D 401/04 directly linked by a ring-member-to-ring-member bond

Abstract

The present invention relates to a new compound of formula (I)

6-(5-cyano-2-hydroxy-1H-indol-3-yl)pyridine-3-carboxylic acid or a pharmaceutically acceptable salt thereof, in an essentially pure and isolated form, pharmaceutical formulations containing said compounds, to the use of said active compounds in therapy, and methods of prevention and/or treatment of conditions associated with glycogen synthase kinase-3 related disorders, comprising administering to a mammal, including human in need of such prevention and/or treatment, a therapeutically effective amount of said compound, as well as a process for preparing said compound.

Claims

1. A compound of formula (I)

2. A pharmaceutical formulation comprising as active ingredient a therapeutically effective amount of the compound according to claim 1, optionally in association with diluents, excipients or inert carriers.

3. A pharmaceutical formulation according to claim 2 in the form of an injectable solution comprising the compound of formula (I) as defined in claim 1, sterile water, and, if necessary, either a base, particularly sodium hydroxide, or an acid, particularly hydrochloric acid, to bring the pH of the final formulation to a pH in the range of about 4 to 6, and optionally a surfactant.

4. An injectable solution according to claim 3, where the pH is about 5.

5. A compound as defined in claim 1 for use in therapy.

7. A method of prevention and/or treatment of conditions associated with glycogen synthase kinase-3, comprising administering to a mammal, including human in need of such prevention and/or treatment, a therapeutically effective amount of a compound as defined in claim 1.

8. A method of prevention and/or treatment of cognitive disorders, comprising administrering to a mammal, including human in need of such prevention and/or treatment, a therapeutically effective amount of a compound as defined in claim 1.

9. The method according to claim 8, wherein the cognitive disorder is dementia, Cognitive Deficit in Schizophrenia (CDS), Mild Cognitive Impairment (MCI), Age-Associated Memory Impairment (AAMI), Age-Related Cognitive Decline (ARCD) or Cognitive Impairement No Dementia (CIND).

10. The method according to claim 9, wherein the disease is Cognitive Deficit in Schizophrenia.

11. The method according to claim 9, wherein the dementia is associated with neurofibrillar tangle pathologies.

12. The method according to claim 9, wherein the dementia is Frontotemporal dementia (FTD), Frontotemporal dementia Parkinson'"'"'s Type (FTDP), progressive supranuclear palsy (PSP), Pick'"'"'s Disease, Niemann-Pick'"'"'s Disease, corticobasal degeneration, traumatic brain injury (TBI) or dementia pugilistica.

13. The method according to claim 9, wherein the dementia is Alzheimer'"'"'s Disease (AD), Down syndrome, vascular dementia, Parkinson'"'"'s Disease (PD), postencephelatic parkinsonism, dementia with Lewy bodies, HIV dementia, Huntington'"'"'s Disease, amyotrophic lateral sclerosis (ALS), motor neuron diseases (MND), Creuztfeld-Jacob'"'"'s disease or prion diseases.

14. The method according to claim 13, wherein the disease is Alzheimer'"'"'s Disease.

15. The method according to claim 14, wherein the treatment is in the delay of the disease progression of Alzheimer'"'"'s Disease.

16. A method of prevention and/or treatment of attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD) or affective disorders, comprising administrering to a mammal, including human in need of such prevention and/or treatment, a therapeutically effective amount of a compound as defined in of claim 1.

17. The method according to claim 16, wherein the affective disorders are Bipolar Disorder including acute mania, bipolar depression, bipolar maintenance, major depressive disorders (MDD) including depression, major depression, mood stabilization, schizoaffective disorders including schizophrenia, or dysthymia.

18. A method of prevention and/or treatment of Type I diabetes, Type II diabetes, diabetic neuropathy, alopecia, inflammatory diseases or cancer, comprising administrering to a mammal, including human in need of such prevention and/or treatment, a therapeutically effective amount of a compound as defined in claim 1.

19. A method of prevention and/or treatment of bone related disorders or conditions comprising administrering to a mammal, including human in need of such prevention and/or treatment, a therapeutically effective amount of a compound as defined in claim 1.

20. A method of prevention and/or treatment of osteoporosis comprising administrering to a mammal, including human in need of such prevention and/or treatment, a therapeutically effective amount of a compound as defined in claim 1.

21. A method of increasing bone formation comprising administrering to a mammal, including human in need of such prevention and/or treatment, a therapeutically effective amount of a compound as defined in claim 1.

22. A method of increasing cancellous bone formation and/or new bone formation comprising administrering to a mammal, including human in need of such prevention and/or treatment, a therapeutically effective amount of a compound as described in claim 1.

23. A method of increasing bone mineral density comprising administrering to a mammal, including human in need of such prevention and/or treatment, a therapeutically effective amount of a compound as defined in claim 1.

24. A method of reducing the incidence of fracture comprising administrering to a mammal, including human in need of such prevention and/or treatment, a therapeutically effective amount of a compound as defined in claim 1.

25. A method of enhancing fracture healing comprising administrering to a mammal, including human in need of such prevention and/or treatment, a therapeutically effective amount of a compound as described in claim 1.

26. A process for preparing the compound of formula (I) according to claim 1, by

ai) reacting a compound of formula (II), with a compound of formula (A), where Hal is halogen and R¹ is C1-6 alkyl, in the presence of a base under inert atmosphere in an appropriate solvent at a temperature between +10°

C. and +150°

C.,

27. A process according to claim 26, where the base is lithium hydride.

6. A method of using 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1H-indole-5-carbonitrile to administer a metabolite of formula (I), the 6-(5-cyano-2-hydroxy-1H-indol-3-yl)pyridine-3-carboxylic acid or a pharmaceutically acceptable salt thereof, in an essentially pure and isolated form.